Quick Answer
Mineralys Therapeutics, Inc. reported Net Income of -$154.65 million for fiscal year 2025.
Mineralys Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$154.65M +13.0% |
-$177.81M -147.3% |
-$71.90M -141.3% |
-$29.80M | — |
| Diluted EPS | -$2.29 +37.4% |
-$3.66 -83.9% |
-$1.99 +65.5% |
-$5.77 | — |
| Total Assets | $661.81M +221.4% |
$205.90M -18.2% |
$251.64M +119.9% |
$114.44M | — |
| Cash and Equivalents | $172.92M +51.6% |
$114.09M +131.4% |
$49.30M -43.8% |
$87.70M | — |
| Stockholders Equity | $646.69M +238.1% |
$191.26M -20.7% |
$241.15M +561.4% |
-$52.27M -128.0% |
-$22.93M |
| R&D Expense | $132.01M -21.7% |
$168.58M +139.6% |
$70.36M +168.0% |
$26.25M | — |
| Operating Income | -$170.60M +11.3% |
-$192.40M -127.3% |
-$84.66M -168.9% |
-$31.48M | — |
| Shares Outstanding | 81.54M +63.7% |
49.82M +21.1% |
41.13M +540.8% |
6.42M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$36.93M | +34.5% | +14.7% |
| Diluted EPS | September 30, 2025 | -$0.52 | +54.0% | +21.2% |
| Total Assets | September 30, 2025 | $599.95M | +123.6% | +78.7% |
| Cash and Equivalents | September 30, 2025 | $217.60M | +123.7% | +113.8% |
| Stockholders Equity | September 30, 2025 | $576.43M | +143.3% | +83.8% |
| R&D Expense | September 30, 2025 | $31.45M | -41.7% | -17.8% |
| Operating Income | September 30, 2025 | -$41.13M | +31.6% | +12.0% |
| Shares Outstanding | September 30, 2025 | 78.97M | +58.7% | +20.2% |
- Mineralys Therapeutics, Inc. reported Net Income of -$154.65 million for fiscal year 2025.
- Mineralys Therapeutics, Inc. showed an increase of +13.0% in Net Income compared to the prior fiscal year.
- Mineralys Therapeutics, Inc. reported Diluted EPS of $2.29 per share (loss) for fiscal year 2025.
- Mineralys Therapeutics, Inc. showed an increase of +37.4% in Diluted EPS compared to the prior fiscal year.
- Mineralys Therapeutics, Inc. reported Total Assets of $661.81 million for fiscal year 2025.
- Mineralys Therapeutics, Inc. showed an increase of +221.4% in Total Assets compared to the prior fiscal year.
- Mineralys Therapeutics, Inc. reported Cash and Equivalents of $172.92 million for fiscal year 2025.
- Mineralys Therapeutics, Inc. showed an increase of +51.6% in Cash and Equivalents compared to the prior fiscal year.
- Mineralys Therapeutics, Inc. reported Stockholders Equity of $646.69 million for fiscal year 2025.
- Mineralys Therapeutics, Inc. showed an increase of +238.1% in Stockholders Equity compared to the prior fiscal year.
- Mineralys Therapeutics, Inc. reported R&D Expense of $132.01 million for fiscal year 2025.
- Mineralys Therapeutics, Inc. showed a decrease of -21.7% in R&D Expense compared to the prior fiscal year.
- Mineralys Therapeutics, Inc. reported Operating Income of -$170.60 million for fiscal year 2025.
- Mineralys Therapeutics, Inc. showed an increase of +11.3% in Operating Income compared to the prior fiscal year.
- Mineralys Therapeutics, Inc. reported Shares Outstanding of 81.54 million shares for fiscal year 2025.
- Mineralys Therapeutics, Inc. showed an increase of +63.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: